MAP2K7 and melanoma: Therapeutic options for BRAF-mutated melanoma in the first line include combinations of ICIs, nivolumab alone or with ipilimumab and pembrolizumab, or BRAF and MEK inhibitors (BRAFi/MEKi), dabrafenib and trametinib, encorafenib and binimetinib, and vemurafenib and cobimetinib [1].